- Novo Nordisk will present 23 abstracts at ObesityWeek 2025 in Atlanta.
- OASIS 4 trial data will focus on oral semaglutide's impact on cardiometabolic health.
- REDEFINE trial will highlight CagriSema's potential in obesity management.
- STEP UP trial will assess semaglutide's efficacy in obesity-related complications.
Overview
Novo Nordisk will present new data on oral semaglutide 25 mg and CagriSema at ObesityWeek 2025 in Atlanta. The presentations will include 23 abstracts focusing on weight loss efficacy and cardiometabolic health.
OASIS 4 Trial
The OASIS 4 trial will provide insights into the impact of oral semaglutide 25 mg on cardiometabolic health among adults with obesity or overweight. It will also explore improvements in blood sugar and cardiovascular risk factors, as well as the efficacy of semaglutide across different formulations in women's health.
REDEFINE Trial
New data from the REDEFINE trial will highlight the innovative pipeline of CagriSema, focusing on its potential for cardiovascular risk reduction and achievement of clinically relevant treatment targets for obesity management.
STEP UP Trial
The STEP UP trial will assess semaglutide 2.4 mg and 7.2 mg, examining the risk of obesity-related complications using clinically relevant treatment targets.
Presentation Schedule
Key presentations include the efficacy of oral semaglutide in people with poor physical function, improvements in glycemic parameters, and indirect comparisons of oral versus injectable semaglutide. CagriSema's impact on hsCRP and predicted ASCVD risk will also be discussed.
